Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

View:
Post by bunser49 on Sep 14, 2016 7:56pm

Seeking Alpha

According to Seeking Alpha, in after hours at 5:25 pm, ARZ is down 3.9%
Comment by GoldenDilemma on Sep 14, 2016 8:10pm
old news.  https://www.nasdaq.com/symbol/arlz/after-hours
Comment by kuatolives on Sep 14, 2016 8:13pm
Doesn't take 3 hours to craft an email either. Does the FDA work till all hours or are we screwed?
Comment by GoldenDilemma on Sep 14, 2016 8:32pm
Kuato, few cases come to mind of late hour releases. Both good and bad. PGNX, NEOS, RLYP... Bad: CHMA, ADMA, PTLA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities